Drug Profile
Vilobelimab - InflaRx
Alternative Names: CaC-P29; Gohibic; IFX-1; Vilobelimab-InflaRxLatest Information Update: 06 Feb 2024
Price :
$50
*
At a glance
- Originator InflaRx
- Class Anti-infectives; Anti-inflammatories; Antineoplastics; Antivirals; Monoclonal antibodies; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Complement C5a inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Registered COVID-19 pneumonia
- Phase III Pyoderma gangrenosum
- Phase II Hidradenitis suppurativa; Squamous cell cancer
- Suspended Granulomatosis with polyangiitis; Microscopic polyangiitis
- No development reported Inflammation
- Discontinued Sepsis; Systemic inflammatory response syndrome
Most Recent Events
- 11 Oct 2023 Updated efficacy and adverse events data from the phase II/III PANAMO trial in Pneumonia presented at the IDWeek 2023 (IDW-2023)
- 31 Aug 2023 Preregistration for COVID-19 pneumonia in European Union (IV)
- 15 Aug 2023 Phase-III clinical trials in Pyoderma gangrenosum in Australia (IV) (NCT05964413)